If you've had problems with one delivery method, the other might work differently for you
The market refers to the global production, trade, and consumption of GLP-1 Receptor Agonists, focusing on injectable formulations used to treat type 2 diabetes and obesity, with a significant emphasis on their efficacy, safety, and increasing adoption in diabetes care.
The maximum damages sought in the case were $1.3 billion, but the likely recovery was estimated at $424 million
Similar to GLP-1(7-37), exenatide also acts as an agonist for GLP-1(7-37), but shows resistance to DPP-4 degradation and has a lower renal clearance rate in human, making exenatide the first successfully developed GLP-1 drug [6]
doi: 10.1016/J.LANEPE.2022.100318